Pfizer’s RSV vaccine candidate shows promise in older adults study
It is estimated that RSV infections in older adults account for 177,000 hospitalisations and 14,000 deaths each year in the US alone
Read More
Tag: RSVpreF
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
